Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Ps
Tweet Content
Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Psoriasis. 465 patients given either PBO, MIR (2 doses) or SEC. Wk 52 MIR PASI90 PASI 90 (81%) vs SEC 69% https://t.co/EBCBUjkyWG
Links
Show on Archive Page
On
Display in Search Results
On